RGLS Regulus Therapeutics Inc
Price (delayed)
$3.49
Market cap
$231.19M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.82
Enterprise value
$192.87M
Regulus Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop
Highlights
RGLS's debt has dropped by 89% year-on-year and by 42% since the previous quarter
RGLS's EPS is up by 48% year-on-year and by 23% since the previous quarter
Regulus Therapeutics's net income has plunged by 54% YoY and by 11% from the previous quarter
Regulus Therapeutics's quick ratio has decreased by 25% from the previous quarter
Key stats
What are the main financial stats of RGLS
Market
Valuations
Earnings
Shares outstanding
66.24M
Market cap
$231.19M
Enterprise value
$192.87M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.99
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$50.04M
Net income
-$46.36M
EBIT
-$46.2M
EBITDA
-$45.85M
Free cash flow
-$42.01M
Per share
Balance sheet
Liquidity
EPS
-$0.82
EPS diluted
-$0.82
Free cash flow per share
-$0.75
Book value per share
$1.17
Revenue per share
$0
TBVPS
$1.49
Total assets
$84.18M
Total liabilities
$7.77M
Debt
$274,000
Equity
$76.41M
Working capital
$74.85M
Debt to equity
0
Current ratio
10.98
Quick ratio
10.11
Net debt/EBITDA
0.84
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-46.8%
Return on equity
-50.3%
Return on invested capital
-70.5%
Return on capital employed
-60.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RGLS stock price
How has the Regulus Therapeutics stock price performed over time
Intraday
26.45%
1 week
73.63%
1 month
101.73%
1 year
44.21%
YTD
120.89%
QTD
99.43%
Financial performance
How have Regulus Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$50.04M
Net income
-$46.36M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 61% year-on-year and by 12% since the previous quarter
Regulus Therapeutics's net income has plunged by 54% YoY and by 11% from the previous quarter
Growth
What is Regulus Therapeutics's growth rate over time
Valuation
What is Regulus Therapeutics stock price valuation
P/E
N/A
P/B
2.99
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
RGLS's EPS is up by 48% year-on-year and by 23% since the previous quarter
The stock's price to book (P/B) is 69% more than its 5-year quarterly average of 1.4 and 69% more than its last 4 quarters average of 1.4
Regulus Therapeutics's equity has decreased by 12% from the previous quarter
Efficiency
How efficient is Regulus Therapeutics business performance
The ROIC has soared by 92% YoY and by 4.3% from the previous quarter
Regulus Therapeutics's return on equity has surged by 54% YoY and by 5% QoQ
RGLS's return on assets is up by 42% year-on-year and by 3.7% since the previous quarter
Dividends
What is RGLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RGLS.
Financial health
How did Regulus Therapeutics financials performed over time
Regulus Therapeutics's total assets has surged by 174% YoY but it has decreased by 10% QoQ
Regulus Therapeutics's quick ratio has decreased by 25% from the previous quarter
RGLS's debt is 100% smaller than its equity
The debt to equity has plunged by 100% from the previous quarter and by 100% YoY
RGLS's debt has dropped by 89% year-on-year and by 42% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.